Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
← catalyst calendarNCT04557449 · readout in 35 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
362actual
Sites
38
Countries
Argentina, China, Czechia +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-09-23 | actual | When the study began enrolling |
| Primary completion | 2026-09-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-23 | estimated | The whole study's end, after follow-up |
| First posted | 2020-09-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Liposarcoma
- Prostate Cancer
- Breast Neoplasms
- Adenocarcinoma of Lung
Interventions
- Drug: PF-07220060
- Combination product: Letrozole — also filed as Femara
- Combination product: Fulvestrant — also filed as Faslodex
- Drug: Midazolam
- Combination product: Enzalutamide — also filed as Xtandi
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with dose limiting toxicities in the Dose Escalation Portion
measured Baseline up to day 28 of Cycle 1.
Incidence of clinically significant AEs
measured Weekly during Cycle 1 and 2 and then every 28 days through study completion, up to approximately 24 months; Each cycle is 28 days
Incidence of clinically significant laboratory assessments
measured Weekly during Cycle 1 and 2 (each cycle is 28 days) and then every 28 days through study completion, up to approximately 24 months
Incidence of clinically significant abnormal vital and ECG parameters
measured Day 1, Day 8, Day 15 of Cycle 1 and starting from Cycle 2, and then every 28 days through study completion, up to approximately 24 months (Each cycle is 28 days)
Food Effect
measured Day -7 through the end of Cycle 1
DDI
measured D1 to the end of Cycle 1
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed